Search

Your search keyword '"Pashos, CL"' showing total 285 results
Start Over Author "Pashos, CL"
285 results on '"Pashos, CL"'

1. Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan

Author

Yamabe K, Liebert R, Flores N, and Pashos CL

Subjects
activity impairment, costs, healthcare resource utilization, health-related quality of life, inflammatory bowel disease, work productivity impairment, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Kaoru Yamabe,1 Ryan Liebert,2 Natalia Flores,2 Chris L Pashos3 1Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Nihonbashi, Chuouku, Tokyo 103-8668, Japan; 2Health Outcomes Research, Kantar Health, New York, NY 10010, USA; 3Global Outcomes and Epidemiology Research, Data Sciences Institute, Takeda Pharmaceuticals International Inc., Cambridge, MA, 02139, USA Purpose: Previous Japanese studies have not compared health-related quality of life (HRQoL), work productivity and activity impairment, health care resource utilization (HRU), and costs in inflammatory bowel disease (IBD) patients with non-IBD controls, leading to insufficient evidence regarding IBD’s true burden. The aim of this study was to examine the impact of IBD on patient-reported outcomes and costs among Japanese adults (≥18 years). Patients and methods: This retrospective cross-sectional study used data from the 2012–2014 Japan National Health and Wellness Survey (N=83,505). HRQoL (SF-36v2), work productivity and activity impairment (work productivity and activity impairment-General Health Questionnaire), HRU, and annual costs were compared between respondents with IBD (n=441) and non-IBD controls (n=82,944), and within IBD subtypes (Crohn’s disease [CD] and ulcerative colitis [UC]) using chi-square and ANOVA tests. Results: Mental Component Summary (MCS), Physical Component Summary (PCS), and health state utility (Short-Form-6 Dimensions [SF-6D]) scores were significantly lower in IBD respondents than in controls (differences of 2.2 points, 2.6 points, and 0.041 points, respectively; all P

Published
2019

2. Health-related quality of life outcomes, economic burden, and associated costs among diagnosed and undiagnosed depression patients in Japan

Author

Yamabe K, Liebert R, Flores N, and Pashos CL

Subjects
Activity impairment, direct costs, healthcare resource use, health-related quality of life, indirect costs, work productivity impairment, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Kaoru Yamabe,1 Ryan Liebert,2 Natalia Flores,2 Chris L Pashos3 1Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Nihonbashi, Chuouku, Tokyo 103-8668, Japan; 2Health Outcomes Research, Kantar Health, New York, NY 10010, USA; 3Global Outcomes & Epidemiology Research, Data Sciences Institute, Takeda Pharmaceuticals International, Inc., Cambridge, MA 02139, USA Purpose: Depression is associated with substantial health and economic burden. This study examined the impact of diagnosed and undiagnosed depression on health-related outcomes and costs among Japanese adults. Methods: A retrospective, observational study was conducted using 2012–2014 Japan National Health and Wellness Survey (N=83,504) data. Differences between respondents diagnosed with depression (n=2,843) and undiagnosed with depression (weighted n=2,717) and controls without depression (weighted n=2,801) in health-related quality of life, impairment to work productivity and daily activities (Work Productivity and Activity Impairment Questionnaire), health care resource utilization, and annual costs were evaluated. Propensity score weighting and weighted generalized linear models were used to compare groups on the outcome variables, after adjusting for covariates. Results: Overall, respondents with undiagnosed depression had significantly better outcomes than those diagnosed with depression, but significantly worse outcomes than controls (for all, P

Published
2019

3. Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries

Author

Yamabe K, DiBonaventura MD, and Pashos CL

Subjects
Activity impairment, direct costs, healthcare resource utilization, health status, indirect costs, work productivity impairment, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Kaoru Yamabe,1 Marco D DiBonaventura,2 Chris L Pashos3 1Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuouku, Tokyo 103-8668, Japan; 2Health Outcomes, Kantar Health, New York, NY 10010, USA; 3Global Outcomes and Epidemiology Research. Data Sciences Institute, Takeda Pharmaceutical International, Cambridge, MA 02139, USA Purpose: Multiple sclerosis (MS) imposes a huge burden on patients. This study examined the relationship between MS and health-related and economic burden in Japan; secondarily, health status was compared across patients with MS in Japan, US, and five European Union (5EU) countries (France, Germany, Italy, Spain, and UK).Methods: A retrospective cross-sectional study was conducted using self-reported data from 2009 to 2014 Japan National Health and Wellness Survey (n=145,759). Health status, work productivity loss, activity impairment, health care resource utilization, and annual costs associated with MS (n=85) were compared with controls without MS (n=145,674). Propensity score matching and multivariable linear regressions determined the effect of MS after controlling for confounders. Health status in Japan was also compared with that of 5EU (n=62) and US (n=67) patients with MS.Results: Patients with MS in Japan reported significantly worse health status via mental component summary score (MCS; 40.1 vs 45.8) and physical component summary score (PCS; 41.4 vs 51.2) and health state utility scores (0.63 vs 0.74; all P

Published
2019

4. Lessons learned by NICE using an AI platform to replicate literature surveillance tasks

Author

Langford, P, Chow, T, Raynor, M, Tuvey, D, Knapton, N, Casey, M, Pashos, CL, Michelson, M, and Nolan, K

Subjects
NICE, ddc: 610, Medicine and health, literature surveillance, artificial intelligence
Abstract

Introduction: A challenge in evidence surveillance is the rapid pace of publication and extensive volume of literature. Yet, the literature must be reviewed to determine fit across a number of topics. At NICE, for instance, there are currently over 25,000 evidence based recommendations in its guidance. [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

5. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors

Author

Kit N. Simpson, Seema Haider, Margaret Tawadrous, Richard Chambers, L. Boulanger, Albert W. Wu, Katherine Nedrow, Pashos Cl, and S.Y. Chen

Subjects
medicine.medical_specialty, Efavirenz, business.industry, Nausea, Health Policy, Incidence (epidemiology), virus diseases, Pharmacy, Rash, Surgery, chemistry.chemical_compound, Infectious Diseases, chemistry, Internal medicine, Propensity score matching, medicine, Vomiting, Pharmacology (medical), medicine.symptom, business, Adverse effect
Abstract

Objectives The aim of the study was to assess the incidence and costs of adverse events (AEs) among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) from the health care system perspective. Methods US medical and pharmacy claims during 2004−2009 were examined to select adult new NNRTI users with HIV infection. The incidence of selected AEs and time to occurrence were assessed during the first year. Episodes of care for each AE were identified using claims associated with AE management. For each AE, a propensity score model was used to match patients with an AE to those without (1:4) based on the propensity of having an AE. Mean total health care costs, AE-associated costs and incremental costs per episode, and annual total health care costs per patient were calculated. Results Of the 2548 NNRTI-treated patients, 29.3% experienced AEs. The incidence ranged from 0.4 episodes/1000 person-years for suicide/self-injury to 14.9 episodes/1000 person-years for dizziness, 49.8 episodes/1000 person-years for depression and 150.3 episodes/1000 person-years for lipid disorder. The mean AE-associated cost (duration) per episode ranged from $586 (88 days) for lipid disorder to $975 (33 days) for rash, $2760 (73 days) for sleep-related symptoms and $4434 (41 days) for nausea/vomiting. The mean incremental cost per episode ranged from $1580 for rash to $2032 for lipid disorder, $8307 for sleep-related symptoms and $12 833 for nausea/vomiting. During the 12 months following NNRTI initiation, the mean annual total health care cost was $27 299 (efavirenz: $26 185; other NNRTIs: $34 993) and AE-associated costs were $608 (efavirenz: $554; other NNRTIs: $979) among all NNRTI users. Conclusions With treatment increasing patient survival, comparisons of therapeutic regimens should consider treatment-associated AEs. Findings from this study could be informative for clinicians and payers in managing HIV infection with NNRTIs.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results